Lupin Limited (LUPIN) receives U.S. FDA approval for Pitolisant Tablets, marking a significant milestone in its pharmaceutical portfolio.
Dishman Carbogen Amcis Limited (DCAL) reports Q1FY27 results with net revenue dipping 4.29%, driven by CDMO segment decline.
Rubicon Research Limited (NSE: RUBICON) stock breaks out, moving up 6% intraday to ₹1723.7, clearing its 6M resistance trendline.
IPCA Laboratories Limited (NSE: IPCALAB) stock price moves up 10% intraday to ₹1910.0, extending gains and nearing resistance at ₹1970.
IPCA Laboratories Limited (IPCALAB) stock moves up 7% intraday to ₹1865.1, extending gains in the Healthcare sector.
Natco Pharma Limited (NATCOPHARM) experiences a 6% intraday decline to ₹892.6, signaling a breakdown in trendline status.
Alkem Laboratories Limited (ALKEM) announces 11% revenue growth for Q1FY27, with strong performance in India and international markets.
Marksans Pharma Limited (MARKSANS) stock clears its 6M resistance trendline, gaining 5% intraday. This breakout move is backed by Q1fy27 profitability at all.
Gaudium IVF and Women Health Limited (NSE: GAUDIUMIVF) reports steady Q1FY27 revenue of ₹19.4 Cr, up 9.13% YoY.
Zota Health Care Limited (ZOTA) reports a 67.59% YoY revenue growth in Q1FY27, reaching ₹17,360.23 lakhs, driven by network expansion.